SCHEMBL1503276

SCHEMBL1503276

Cc1c(COCc2ccc(F)cc2)cnc(C(=O)NO)c1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.40
KDM4E B2RXH2 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
ABHD6 Q9BV23 1/20 0.39
GRM5 P41594 1/20 0.39
KMT2A Q03164 2/20 0.36
RAB9A P51151 1/20 0.36
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HDAC1 Q13547 4/20 0.35
MAOB P27338 2/20 0.35
MEN1 O00255 1/20 0.35
MAOA P21397 2/20 0.35
HDAC3 O15379 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
EGLN1 Q9GZT9 1/20 0.35
HDAC4 P56524 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1503227 0.88 HDAC6 (0.40) ARKDM4EL3MBTL1RAB9AALDH1A1
SCHEMBL1503249 0.88 MAOB (0.39) ARCNR1RAB9AHDAC1MAOB
SCHEMBL29829420 0.87 SMPD1 (0.45) KDM4EL3MBTL1RAB9AALDH1A1LMNA
SCHEMBL28791542 0.87 AR (0.42) ARKDM4EL3MBTL1CNR1CNR2
SCHEMBL2146742 0.87 EGLN1 (0.43) KDM4ECNR2KMT2ARAB9AALDH1A1
SCHEMBL1503201 0.86 MAOB (0.41) HDAC1MAOBHDAC3HDAC2HDAC6
SCHEMBL1503203 0.86 L3MBTL1 (0.40) ARKDM4EL3MBTL1KMT2ARAB9A
SCHEMBL1503263 0.86 MMP1 (0.44) KMT2ARAB9AALDH1A1MAOBMEN1
SCHEMBL12444361 0.79 ALDH1A1 (0.37) KDM4EL3MBTL1CNR1RAB9AALDH1A1
SCHEMBL1503258 0.78 EGFR (0.41) KMT2AALDH1A1HDAC1HDAC3HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8742123-B2 HIV integrase inhibitors from pyridoxine TAIMED BIOLOGICS, INC. (TW) 2014-06-03 US claimed
US-20110178120-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA, INC. (CA) 2011-07-21 US claimed
EP-2300433-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE Ambrilia Biopharma Inc. (CA) 2011-03-30 EP claimed
WO-2009146555-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA INC. (CA) 2009-12-10 WO claimed
US-8742123-B2 HIV integrase inhibitors from pyridoxine TAIMED BIOLOGICS, INC. (TW) 2014-06-03 US disclosed
US-8742123-B2 HIV integrase inhibitors from pyridoxine TAIMED BIOLOGICS, INC. (TW) 2014-06-03 US disclosed
US-20110178120-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA, INC. (CA) 2011-07-21 US disclosed
US-20110178120-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA, INC. (CA) 2011-07-21 US disclosed
EP-2300433-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE Ambrilia Biopharma Inc. (CA) 2011-03-30 EP disclosed
WO-2009146555-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA INC. (CA) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178120-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE PNPO, CCNB1, BLVRB AR 1579/4885KDM4E 1182/4885L3MBTL1 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.